« Back
Home /
Relamorelin (TFA)

Relamorelin (TFA)

Item no.	HY-19884B-50mg
Manufacturer	MedChem Express
CASRN	2863659-22-5
Amount	50 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Molecules
Specific against	other
Purity	99.81
Citations	[1]DeBoer MD, et, al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007 Jun;148(6):3004-12.\|[2]Fischer K, et, al. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Front Nutr. 2015 Jan 12;1:31.\|[3]Zatorski H, et, al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017 Dec;68(6):797-805.\|[4]Matthew Heckroth, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021 Apr 1;55(4):279-299.\|[5]Victor Chedid, et al. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017 Oct;26(10):1189-1197.
Smiles	NC(C1(NC([C@@H](NC([C@H](NC([C@H](NC(C2CCNCC2)=O)CC3=CSC4=CC=CC=C34)=O)CC5=CNC6=CC=CC=C56)=O)CC7=CC=CC=C7)=O)CCNCC1)=O.OC(C(F)(F)F)=O
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	RM-131 (TFA),BIM-28131 (TFA)
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Metabolism-protein/nucleotide metabolism
Manufacturer - Targets	GHSR
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Molecular Weight	905.00
Product Description	Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research[1][2][3][4][5].
Manufacturer - Research Area	Metabolic Disease
Solubility	H2O: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-19884B-50mg-safety-datasheet.pdf